Lavipharm: Investments and acquisitions drive growth and international expansion
Lavipharm Group recorded a 24.1% increase in consolidated sales before clawbacks and rebates, while EBITDA from continuing operations rose by 5.2% in the first half of 2026.
The results confirm the …